Thermogenesis in Adipose Tissue: Adrenergic and Non-Adrenergic Pathways
Md Arafat Hossain1, Ankita Poojari1, Atefeh Rabiee1
1Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA.
Cells
|January 28, 2026
Summary
Obesity management requires new strategies beyond traditional pathways. This review explores non-adrenergic targets and interventions for safe and effective energy expenditure, offering hope for sustainable weight control.
Area of Science:
- Metabolic research
- Adipose tissue biology
- Obesity therapeutics
Background:
- Obesity is a global epidemic driven by energy imbalance.
- Brown (BAT) and beige adipose tissues promote energy expenditure (EE) via non-shivering thermogenesis (NST).
- Canonical adrenergic pathways show limited translational success in humans for obesity treatment.
Purpose of the Study:
- To review alternative, non-adrenergic pathways for activating thermogenesis.
- To evaluate pharmacological and non-pharmacological interventions targeting these pathways.
- To bridge the translational gap between rodent and human obesity research.
Main Methods:
- Comprehensive literature review of alternative thermogenic mechanisms.
- Analysis of G-protein coupled receptors (GPCRs), ion channels, and hormonal signaling.
- Evaluation of interventions including cold exposure, exercise, diet, and novel pharmacological agents.
Main Results:
- Non-adrenergic pathways (e.g., TGR5, GLP-1R, SERCA modulators) offer promising alternatives.
- UCP1-independent mechanisms and futile substrate cycles contribute to thermogenesis.
- Multimodal therapies combining adrenergic and non-adrenergic approaches show potential.
Conclusions:
- Non-adrenergic and UCP1-independent mechanisms are crucial for human thermogenesis.
- Integrating diverse therapeutic strategies is key for effective obesity management.
- Future research should focus on multimodal and tissue-specific approaches for sustainable EE.
Related Concept Videos
Adrenergic Agonists: Therapeutic Uses
1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Adrenergic Neurons: Neurotransmission
5.3K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.3K
Adrenergic Agonists: Therapeutic Classification
1.6K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.6K
Adrenergic Receptors (Adrenoceptors): Classification
4.9K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.9K
Adrenergic Receptors: ɑ Subtype
2.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.9K
Adrenergic Receptors: β Subtype
3.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.7K


